Refining Prognostic Stratification in Clear Cell Renal Cell Carcinoma: Genomic, Tissue-Based, Circulating Biomarkers and Integrated Models
Cancers · 25.04.2026 · 18 (9) · 1371
DOI: 10.3390/cancers18091371 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 25.04.2026. Verfasst von Mariana Bianca Chifu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Morfofunctional Sciences 1, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iași, Romania. Die Arbeit nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Clear cell renal cell carcinoma (ccRCC) is characterized by marked biological heterogeneity, which limits the prognostic accuracy of conventional clinicopathological models. Increasing attention has therefore focused on identification of biomarkers that can enhance risk stratification throughout all stages of the disease. Starting from the current state of the art, this narrative review summarizes and critically appraises the evidence published over the past decade regarding prognostic biomarkers in ccRCC. The analysis is structured into four overarching domains: (i) genomic biomarkers, covering somatic alterations and transcriptomic signatures; (ii) tissue-based biomarkers, including immunohistochemical surrogates and immune microenvironment features; (iii) circulating biomarkers, such as systemic inflammation parameters and indices; and (iv) integrated predictive models, represented by emerging multi-omic approaches. Going through the broad framework of potential prognostic biomarkers, emphasis is placed on their individual and integrative value in relation to classic clinical-pathological factors and survival parameters. At the tissue level, chromosome 3p-related alterations constitute a central molecular feature of ccRCC. Among these, BAP1 loss has emerged as one of the most consistently validated indicators of aggressive tumor behavior. Disruption of the SETD2/H3K36me3 axis and immune-related biomarkers, including PD-L1 expression, have demonstrated prognostic associations in selected settings, although with variable and context-dependent performance. In the circulating compartment, plasma KIM-1 has shown prognostic relevance following nephrectomy, while postoperative detection of circulating tumor DNA (ctDNA) may identify patients at increased risk of recurrence. However, limited analytical sensitivity and methodological heterogeneity currently restrict the broader clinical applicability of ctDNA-based strategies. Systemic inflammatory indices, such as the neutrophil-to-lymphocyte ratio, show reproducible associations with outcomes but largely reflect host inflammatory status rather than tumor-specific biology. However, no single biomarker currently supports routine prognostic implementation in ccRCC. Future progress will likely depend on integrative models combining genomic, tissue-based, immune, and circulating parameters with established clinical variables. Prospective validation and clear demonstration of incremental clinical utility will be essential before such strategies can meaningfully inform therapeutic decision-making.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Morfofunctional Sciences 1, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iași, Romania.
- Department of Pathology, "Dr. C. I. Parhon" University Hospital, 700503 Iași, Romania.
- Department of Preventive Medicine and Interdisciplinarity, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iași, Romania.
- Romanian Medical Science Academy, 030171 Bucharest, Romania.
ORCID-Profile: Andrei Daniel Timofte, Constantin Aleodor Costin, Andreea Rusu
Zitieren
APA
Chifu, M. B., Giușcă, S. E., Timofte, A. D., Costin, C. A., Rusu, A., Ipatov, A. M., & Căruntu, I. D. (2026). Refining Prognostic Stratification in Clear Cell Renal Cell Carcinoma: Genomic, Tissue-Based, Circulating Biomarkers and Integrated Models. Cancers, 18(9), 1371. https://doi.org/10.3390/cancers18091371
Vancouver
Chifu MB, Giușcă SE, Timofte AD, Costin CA, Rusu A, Ipatov AM, et al. Refining Prognostic Stratification in Clear Cell Renal Cell Carcinoma: Genomic, Tissue-Based, Circulating Biomarkers and Integrated Models. Cancers. 2026;18(9):1371. doi:10.3390/cancers18091371
BibTeX
@article{Chifu2026,
author = {Chifu, Mariana Bianca and Giușcă, Simona Eliza and Timofte, Andrei Daniel and Costin, Constantin Aleodor and Rusu, Andreea and Ipatov, Ana-Maria and Căruntu, Irina Draga},
title = {Refining Prognostic Stratification in Clear Cell Renal Cell Carcinoma: Genomic, Tissue-Based, Circulating Biomarkers and Integrated Models},
journal = {Cancers},
year = {2026},
volume = {18},
number = {9},
pages = {1371},
doi = {10.3390/cancers18091371}
}
EUVIMED